Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 0 · 0%Moderate 1 · 25%High 0 · 0%

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.43 [0.22, 0.81]
5 studies · 1089 participants
Moderate

Low molecular weight heparin vs no LMWH

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 0.95 [0.62, 1.46]
5 studies · 1089 participants
Very low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.83 [0.44, 7.61]
2 studies · 327 participants
Very low

Low molecular weight heparin vs vitamin K antagonist (VKA)

Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters

It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).

1 finding from 1 review

Anticoagulation for people with cancer and central venous catheters 2018 · Cochrane Headline outcomes only
RR 1.61 [0.75, 3.46]
2 studies · 317 participants
Very low